Contributing factors in trimethoprim-sulfamethoxazoleinduced tremor in Pneumocystis jirovecii pneumonia
Year: 2024
Type: article
Study design: Case Report
Abstract: Trimethoprim-sulfamethoxazole (TMP-SMX) is the first-line antibiotic for the treatment of opportunistic infections, including Pneumocystis jirovecii pneumonia (PJP), in immunocompromised patients.[1,2] Most patients tolerate the treatment well, particularly in lower doses, but dose-related dermatological, renal, and hepatic reactions are the most common adverse events (AEs).[1,2] Although neurological AEs are rare, TMP-SMXinduced tremor has been infrequently reported since 1988 as a reversible neurotoxic AE at higher doses, mostly in immunocompromised patients.[3][4][5][6] Herein, we presented a patient with tremor induced by both mild hypoxia and TMP-SMX during PJP treatment.
Source: Turkish Journal Of Neurology
Authors: Melek Kandemir Yılmaz, Figen Atalay
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4402367855